{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:35:43Z","timestamp":1791362143015,"version":"4.3.1"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,7,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Onycholysis and skin toxicity occur in approximately 30% of patients treated with docetaxel. We investigated the efficacy and safety of an Elasto-Gel (84400 APT Cedex, Akromed, France) frozen glove (FG) for the prevention of docetaxel-induced onycholysis and skin toxicity. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients receiving docetaxel 75 mg\/m<jats:sup>2<\/jats:sup> alone or in combination chemotherapy were eligible for this case-control study. Each patient wore an FG for a total of 90 minutes on the right hand. The left hand was not protected and acted as the control. Onycholysis and skin toxicity were assessed at each cycle by National Cancer Institute Common Toxicity Criteria and documented by photography. Wilcoxon matched-pairs rank test was used. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Between August 2002 and September 2003, 45 patients were evaluated. Onycholysis and skin toxicity were significantly lower in the FG-protected hand compared with the control hand (P = .0001). Onycholysis was grade (G) 0 in 89% v 49% and G1 to 2 in 11% v 51% for the FG-protected hand and the control hand, respectively. Skin toxicity was G0 in 73% v 41% and G1 to 2 in 27% v 59% for the FG-protected and the control hand, respectively. Median time to nail and skin toxicity occurrence was not significantly different between the FG-protected and the control hand, respectively (106 v 58 days for nail toxicity; 57 v 58 days for skin toxicity). Five patients (11%) experienced discomfort due to cold intolerance. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> FG significantly reduces the nail and skin toxicity associated with docetaxel and provides a new tool in supportive care management to improve a patient's quality of life. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.15.651","type":"journal-article","created":{"date-parts":[[2005,6,30]],"date-time":"2005-06-30T01:12:53Z","timestamp":1120093973000},"page":"4424-4429","source":"Crossref","is-referenced-by-count":173,"title":["Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onycholysis and Cutaneous Toxicity of the Hand"],"prefix":"10.1200","volume":"23","author":[{"given":"Florian","family":"Scott\u00e9","sequence":"first","affiliation":[{"name":"From the Department of Medical Oncology, Georges Pompidou European Hospital; Urology Department, Cochin Hospital, Paris; and Medical Oncology Department, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Tourani","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Georges Pompidou European Hospital; Urology Department, Cochin Hospital, Paris; and Medical Oncology Department, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugeniu","family":"Banu","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Georges Pompidou European Hospital; Urology Department, Cochin Hospital, Paris; and Medical Oncology Department, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Peyromaure","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Georges Pompidou European Hospital; Urology Department, Cochin Hospital, Paris; and Medical Oncology Department, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Levy","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Georges Pompidou European Hospital; Urology Department, Cochin Hospital, Paris; and Medical Oncology Department, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Marsan","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Georges Pompidou European Hospital; Urology Department, Cochin Hospital, Paris; and Medical Oncology Department, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Magherini","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Georges Pompidou European Hospital; Urology Department, Cochin Hospital, Paris; and Medical Oncology Department, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Fabre-Guillevin","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Georges Pompidou European Hospital; Urology Department, Cochin Hospital, Paris; and Medical Oncology Department, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Andrieu","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Georges Pompidou European Hospital; Urology Department, Cochin Hospital, Paris; and Medical Oncology Department, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Georges Pompidou European Hospital; Urology Department, Cochin Hospital, Paris; and Medical Oncology Department, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.2.314"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1238"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2301"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Gligorov J, Lotz JP: Preclinical pharmacology of the taxanes: Implications of the differences. Oncologist 9:3,2004-8,  (suppl 2)","DOI":"10.1634\/theoncologist.9-suppl_2-3"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.1061"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Markman M: Managing taxane toxicities. Support Care Cancer 11:144,2003-147,","DOI":"10.1007\/s00520-002-0405-9"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000026486.56886.18"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg050"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200001040-00004"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199921030-00004"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Vanhooteghem O, Richert B, Vindevoghel A, et al: Subungual abscess: A new ungual side-effect related to docetaxel therapy. Br J Dermatol 143:462,2000-464,","DOI":"10.1046\/j.1365-2133.2000.03692.x"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010964"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1159\/000018132"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.3.1.57"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Battegay EJ: Angiogenesis: Mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 73:333,1995-346,","DOI":"10.1007\/BF00192885"},{"key":"R16","unstructured":"Spadaro P, Maisano R, Mare M: Is there any correlation between decreased serum vascular endothelial growth factor (sVEGF) levels and nail toxicity in responsive metastatic breast cancer (MBC) patients treated with weekly docetaxel? Preliminary data of a phase II study. Proc Am Soc Clin Oncol 20:2002 (abstr 1952)"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016002329546"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00012-5"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(96)00374-7"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Ridderheim M, Bjurberg M, Gustavsson A: Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: A pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer 11:371,2003-377,","DOI":"10.1007\/s00520-003-0451-y"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.3.449"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.9.1167"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004268321"},{"key":"R24","unstructured":"Roche H, Fumoleau P, Speilmann M: Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Breast Cancer Res Treat 88:S16,2004,  (suppl 1; abstr 27)"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.15.651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:06:58Z","timestamp":1653512818000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.15.651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,1]]},"references-count":25,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2005,7,1]]}},"alternative-id":["10.1200\/JCO.2005.15.651"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.15.651","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,1]]}}}